Overview

Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This study will be a randomized, blinded, placebo-controlled two-group clinical trial. The independent variable is treatment assignment (active 4-mg nicotine lozenge vs. matching placebo lozenge), and the dependent variables are all tobacco and ST abstinence at 3 and 6 months. ST users will be randomly assigned to either the 4-mg active nicotine lozenge or matching placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Cancer Institute (NCI)
Treatments:
Lobeline
Nicotine